EGFR L747P mutation in one lung adenocarcinoma patient responded to afatinib treatment: a case report

被引：12
|
作者：
Zhou, Tong [1 ]
Zhou, Xiaoyue [1 ]
Li, Peng [1 ]
Qi, Chuang [2 ]
Ling, Yang [1 ]
机构：
[1] Soochow Univ, Dept Med Oncol, Changzhou Canc Hosp, 68 Honghe Rd, Changzhou 213032, Peoples R China
[2] 3D Med Inc, Med Dept, Shanghai 201100, Peoples R China
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷 / 12期
关键词：
RESISTANCE; CANCER;
D O I：
10.21037/jtd.2018.12.26
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：E802 / E805
页数：4
相关论文
共 50 条
  • [1] Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation
    Li, Jisheng
    Zhu, Liping
    Stebbing, Justin
    Peng, Ling
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2022, 18 (05) : 1436 - 1439
  • [2] Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases
    Li, Yibin
    Guo, Weixi
    Jiang, Bin
    Han, Chengkun
    Ye, Feng
    Wu, Jingxun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma
    Yu, Guohua
    Xie, Xiaoxia
    Sun, Dengjun
    Geng, Junzu
    Fu, Fenghua
    Zhang, Liangming
    Wang, Hongbo
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (07): : 8603 - 8606
  • [4] Durable response to osimertinib monotherapy as first line treatment in stage IVB lung adenocarcinoma with atypical EGFR L747P mutation
    Choi, Horyun
    Lee, Yeun Ho
    Kim, Jinah
    Kim, Leeseul
    Kim, Na Hyun
    Chae, Young Kwang
    CANCER RESEARCH, 2022, 82 (12)
  • [5] Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
    Liang, Sheng-Kai
    Ko, Jen-Chung
    Yang, James Chih-Hsin
    Shih, Jin-Yuan
    LUNG CANCER, 2019, 133 : 103 - 109
  • [6] Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report
    Wang, Yu-Ting
    Ning, Wei-Wei
    Li, Jing
    Huang, Jian-An
    JOURNAL OF THORACIC DISEASE, 2016, 8 (07) : E542 - E546
  • [7] CLINICAL PERSPECTIVES ON THE UNCOMMON EGFR P. L747P AND P. L747S MUTATIONS IN LUNG ADENOCARCINOMA: A CASE SERIES STUDY
    Liang, Sheng-Kai
    Ko, Jen-Chung
    Yang, James Chih-Hsin
    Shih, Jin-Yuan
    RESPIROLOGY, 2018, 23 : 291 - 292
  • [8] A rare EGFR mutation L747P conferred therapeutic efficacy to both gefitinib and osimertinib: A case report
    Huang, Xiaojie
    Yang, Yan
    Wang, Pingli
    Wang, Jia
    Chen, Songan
    Mao, Xinru
    Ding, Liren
    LUNG CANCER, 2020, 150 : 9 - 11
  • [9] Case report of a patient with stage IV lung adenocarcinoma and uncommon/compound EGFR mutations who responded to afatinib
    Hirokawa, Hisanori
    Hirata, Hirokuni
    Azuma, Hayase
    Sugitate, Kei
    Soda, Sayo
    Matsushima, Jun
    Fukushima, Yasutsugu
    RESPIRATORY MEDICINE CASE REPORTS, 2024, 51
  • [10] Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib A case report
    Cai, Yangyang
    Wang, Xu
    Guo, Ye
    Sun, Chao
    Xu, Yinghui
    Qiu, Shi
    Ma, Kewei
    MEDICINE, 2019, 98 (01)
12345